metastatic/advanced hepatocellular cancer (mHCC) | ||
mHCC - 1st line (L1) | mHCC - 2nd line (L2) | |
pembrolizumab based treatment | ||
pembrolizumab alone | KEYNOTE-394 KEYNOTE-240 | |
pembrolizumab plus lenvatinib | LEAP 002 |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -